DD-723 Phase III Clinical Trial (Breast)

DD-723 Phase III Clinical Trial - Confirmatory Study in Subjects with Breast Tumor -

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221250

Enrollment

120

Registered

2010-09-27

Start date

2010-09-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects with breast tumor

Interventions

investigational material(s) Generic name etc : DD-723 INN of investigational material : Perflubutane Therapeutic category code : 729 Other diagnostic agents (except extracorporeal diagnostic medicines

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Subjects with focal breast tumors - Subjects scheduled to undergo pathological examination - Subjects aged >=20 years old at the time of informed consent

Exclusion criteria

Exclusion criteria: - Items listed on the package insert (including absolute contraindications, careful administration, and precautions) to ensure safety - Items related to safety and ethics - Items related to surgery, procedures, and treatment influencing efficacy and safety assessment for DD-723 - Subjects who are pregnant, possibly pregnant, or lactating

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy rate of differential diagnosis Assessment by the blinded readers	—

Secondary

Measure	Time frame
Differential diagnostic performance, assessment of tumor extent diagnosis, evaluation of contrast effect Assessment by the blinded readers	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026